NewsRoom Articles - Page 180 of 222

MondayMar 08, 2021 10:50 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Takes Bladder Cancer Battle to Next Level

Imagin Medical has developed a technology, currently entering the manufacturing stage, which it believes will revolutionize bladder cancer surgical imaging The company’s technology, the i/Blue Imaging System, can display blue and white light images of the bladder side-by-side simultaneously, allowing surgeons greater ability to detect and remove tumors Imagin has raised a $2.165 million convertible note offering to fund the company during the manufacturing phase of its surgical imaging system as well as the U.S. Food and Drug Administration (“FDA”) approval process Bladder cancer is one of the most prevalent cancers in the United States, particularly in men, and is…

FridayMar 05, 2021 1:25 pm

How Therapeutic Hypothermia Could Benefit ICU Patients

A recent study discovered how lower temperatures improved a surfactant’s activity, showing that therapeutic hypothermia is a possible treatment option for ARDS, which impacts roughly one-tenth of intensive care unit (“ICU”) patients globally. Apart from patients in ICUs, critical coronavirus patients also suffer from acute respiratory distress syndrome. In layman’s language, therapeutic hypothermia is the intentional cooling of an individual’s body. Research conducted by Chiara Autilio and colleagues from the Jesus Perez-Gil laboratory at the Complutense University of Madrid demonstrates how therapeutic hypothermia works at the molecular level in an individual’s lungs; the research also notes how this method could…

FridayMar 05, 2021 12:36 pm

Brain Scientific Inc. (BRSF) Making EEGs Accessible in Emergency Departments

Head CTs, MRIs are most-used but not most-effective tool for head trauma or neurological issues in triage EEG changed clinical management of 76.2% of patients, even when CT or MRI was available Brain Scientific has overcome key barriers causing EEG underuse in emergency medicine Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, is making EEGs accessible in emergency departments (“ED”) with cutting-edge tech that bridges the widening gap in access to quality care. As the public becomes more aware of head trauma's long-term effects, triages fill up with potential TBIs and acute neurological conditions. Facilities are scrambling to adapt to…

FridayMar 05, 2021 12:21 pm

Predictive Oncology Inc. (NASDAQ: POAI) Announces Fundraising Agreements to Raise Estimated $25M

POAI completes two separate fundraising initiatives: private placement, direct offering. Two fundraising campaigns expected to result in $17.6 million, $7.4 million respectively. Predictive Oncology plans to use funds to pay off debt as well as for working capital, general corporate purposes. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced two funding initiatives that together total an estimated $25 million. The company has entered into securities purchase agreements with institutional and accredited investors (https://ibn.fm/WH4nw) to raise approximately $17.6 million and is involved in a direct offering that is expected…

FridayMar 05, 2021 11:13 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) Get the Green Light for Clinical Trials’ Protocols from Ethics Panels

CNS Pharmaceuticals holds the exclusive worldwide license to the Berubicin chemical compound Berubicin is CNSP’s lead, novel anthracycline candidate for the treatment of glioblastoma multiforme (“GBM”) that was the subject of a previously conducted Phase 1 clinical trial, which had a clinical benefit response rate of 44% CNSP has sublicensed Berubicin to WPD Pharmaceuticals in 31 countries primarily in eastern Europe and western Asia WPD plans to conduct a Phase 2 trial in adults with GBM and a Phase 1 trial for pediatric patients with malignant gliomas CNSP intends to conduct its own Phase 2, potentially pivotal, trial in s…

ThursdayMar 04, 2021 2:30 pm

Researchers Design New Device That Uses Body as a Battery

CU Boulder researchers have designed a low-cost wearable device that uses the human body as a biological battery. The device is made of a stretchy material that allows an individual to wear it as a bracelet, ring or other accessory. The device harnesses an individual’s natural heat and uses thermoelectric generators to turn the internal temperature of an individual’s body into electricity. The paper was published in the “Science Advances” journal. Associate professor at the Paul M. Rady Department of Mechanical Engineering, Jianliang Xiao, who is also the paper’s senior author, stated that the future objective of the researchers is…

ThursdayMar 04, 2021 1:29 pm

RYAH Group Committed to Advancing Telehealth in HIPAA-Compliant Environment

Telehealth sector going through explosive growth; patients' data protection remains key challenge Although relaxed due to COVID-19 outbreak, HIPAA guidelines protecting patients' data security, privacy likely to tighten as pandemic abates RYAH appears ready to respond to strict data security requirements, uses medical data in a HIPAA-compliant setting Telehealth is becoming increasingly popular with patients and doctors alike, but securing the integrity of patient information remains critical. As a company developing proprietary technology supporting a data-driven healthcare approach, RYAH Group appears ready to respond to the strict data security requirements. With patients needing more access to health care, and providers…

ThursdayMar 04, 2021 11:46 am

Brain Scientific (BRSF) Developing State-of-the-Art AI Diagnostic Analytics

BRSF working to improve diagnostics by leveraging AI and machine learning Cloud-based infrastructure, AI-assisted diagnostic analysis is in development phase Brain Scientific creating long-term monitoring capabilities that leads to collection of essential biomarkers Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, is working on developing state-of-the-art AI diagnostic analytics. The company’s two FDA-cleared products — the NeuroCap(TM) and NeuroEEG(TM) — offer cost-effective disposable alternatives to existing electroencephalogram (“EEG”) solutions. These disposable and simple-to-use devices allow medical professionals to collect necessary diagnostic information quickly. But BRSF isn’t stopping there. The company’s…

WednesdayMar 03, 2021 12:26 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Reimagines Technology to Create Better Cancer Outcomes

Archaic technology contributes to dismal recurrence rate in bladder cancer Imagin Medical revolutionizes the way surgeons can visualize cancer to better identify, and remove during surgery There is potential to extend this technology to virtually other endoscopic procedures The battle against cancer is too often set back by crushing blows of recurrence. The disease is insidious. If every single malignant cell of a tumor is not completely removed, it can rebound and attack again. Nowhere is this dismal recurrence more prevalent than in bladder cancer. Caught early, bladder cancer stands a better chance of being successfully treated through surgery and…

WednesdayMar 03, 2021 12:15 pm

Hydrogel Injection Could Change Cardiac Tissue Healing After Heart Attacks

Researchers at Spain’s University of Valladolid, BIOFORGE Labs, the SFI Research Center and CÚRAM have created a hydrogel injectable that may prevent additional damage and assist in repairing heart muscles following a heart attack. Heart disease, or myocardial infarction, is the most common cause of death owing to irreversible damage of cardiac tissue after a heart attack. As tissue regeneration is minimal, any damage to heart muscle can’t be self-repaired. Present-day treatments lack an efficacious way to improve heart muscle repair and prevent death after a heart attack. The project’s lead, Professor Abhay Pandit, scientific director of CÚRAM, explained that…